DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for head and neck squamous cell carcinoma — screening already-approved drugs against its 44-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHead and neck squamous cell carcinoma maps to a 44-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for head and neck squamous cell carcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
mitogen-activated protein kinase 1 (MAPK1) — MAPK1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2~{s}drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8AOJ · 1.12 Å · ligand 1-[(2~{S})-2-(5-methyl-3-pyridin-4-yl-1~{H}-pyrazol-4-yl)pyrrolidin-1-yl]propan-1-one (N8L). Experimental structure, not a prediction.
What the evidence adds up to
In a 2009 review of molecular markers in head and neck squamous cell carcinoma, human papillomavirus was identified as an important cause of oropharyngeal carcinoma, likely representing a distinct mechanism of carcinogenesis from tobacco- and alcohol-associated tumours. Human papillomavirus-associated tumours appeared to have an improved prognosis and might respond differently to treatment. Other markers studied included epidermal growth factor receptor, p53, and p16. Epidermal growth factor receptor inhibitors were described as becoming an important weapon in the therapeutic arsenal, but the review concluded that molecular markers were not yet ready for routine clinical management of patients. A 2005 review noted that several genes and pathways showed substantially altered expression in cancerous versus noncancerous states across studies, but called for further investigation into genomic, proteomic, and functional consequences.
A 2006 symposium on head and neck cancer discussed published Phase II and Phase III data on treatment of locally advanced disease with induction chemotherapy and concurrent chemoradiotherapy. Molecular targets of interest were identified, and preliminary results from trials incorporating molecularly targeted agents were said to show a promising role for these compounds in both locally advanced and recurrent/metastatic squamous cell carcinoma of the head and neck. The symposium concluded that management had evolved considerably and would continue to expand. A 2008 article on unknown primary carcinoma of the head and neck reported that this condition affects 3% to 25% of patients and stated that treatment, best carried out by multidisciplinary teams, is curative for most of these patients.
No concrete numbers for survival, response rates, or sample sizes were provided in any of these abstracts. The 2009 review explicitly stated that molecular markers were not ready for routine use. The 2005 review identified altered gene expression but offered no therapeutic results. The 2006 symposium mentioned promising preliminary results but gave no quantitative data. What remains missing is any completed, controlled trial that reports objective response or survival data for a specific repurposed drug in head and neck squamous cell carcinoma, as well as the patient stratification needed to determine which molecular subtypes might benefit.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Oncology · 2009 · 45 citations
Role of molecular markers and gene profiling in head and neck cancers
AbstractPURPOSE OF REVIEW: To explore the current status of molecular markers in the diagnosis, prognosis, and treatment of squamous cell carcinoma of the head and neck. RECENT FINDINGS: A variety of studies have been undertaken to improve classification of head and neck squamous cell carcinoma. In the past several years, it has become apparent that human papillomavirus is an important cause of oropharyngeal carcinoma, and likely represents a distinct mechanism of carcinogenesis compared to tobacco and alcohol-associated tumors. Human papillomavirus-associated tumors seem to have an improved prognosis, and may respond differently to treatment. Other markers such as epidermal growth factor receptor, p53, p16, and others have been extensively studied. Several of these proteins have been the targets of investigational drugs, and epidermal growth factor receptor inhibitors are becoming an important weapon in our therapeutic arsenal. SUMMARY: Molecular markers have given us new understanding of the pathogenesis of head and neck squamous cell carcinoma. However, these markers are not yet ready to be used in the routine clinical management of patients with these tumors, and further research is needed.
Journal of the National Comprehensive Cancer Network · 2008 · 24 citations
Evaluation and Management of the Unknown Primary Carcinoma of the Head and Neck
AbstractSquamous cell carcinoma of unknown primary origin in the head and neck is encountered as a recurring clinical problem in head and neck cancer clinics, affecting 3% to 25% of patients. This article describes the clinical presentation, appropriate evaluation, and treatment strategies for this important subgroup. Treatment--best carried out with multidisciplinary teams of specialists experienced in the care of head and neck cancer patients--is curative for most of these patients.
AbstractThe current review indicated that there are several genes and pathways that exhibit substantially altered expression in cancerous versus noncancerous states across studies. Further investigation into the genomic, proteomic, and functional consequences of these gene expression alterations may provide insight into the pathophysiology of head and neck squamous cell carcinoma.
Anti-Cancer Drugs · 2016 · 1 citations · open access
Efficacy and safety of vinorelbine in heavily pretreated recurrent/metastatic head and neck squamous cell carcinoma patients
AbstractThe aim of this study was to evaluate the efficacy and tolerance of vinorelbine as a single agent in the treatment of recurrent/metastatic head and neck squamous cell carcinoma. Patients were treated with oral or intravenous vinorelbine according to the pluridisciplinary tumor board's decision. Efficacy and safety outcomes were analyzed retrospectively. Twenty-three patients were included in the study. Sixteen patients (69%) had received at least two previous lines of chemotherapy. The disease control rate was 19%. The median progression-free survival was 2.6 months and the median overall survival was 3.4 months. The rate of grade 3-4 side effects was low (13%). Only one patient discontinued treatment because of side effects. Vinorelbine seems to be a well-tolerated regimen in heavily pretreated patients. However, this regimen does not seem to be efficient enough to be recommended.
Expert Opinion on Pharmacotherapy · 2006 · 0 citations
Multidisciplinary Symposium on Head and Neck Cancer
AbstractThe Multidisciplinary Symposium on Head and Neck Cancer focused on the emerging data that underlie optimal treatment for head and neck cancers, with a particular focus on squamous cell carcinoma of the head and neck. In-depth discussions showcased the published Phase II and Phase III data on the treatment of locally advanced disease with both induction chemotherapy and concurrent chemoradiotherapy. Molecular targets of interest and relevance in this tumour type were identified, as were the agents which target these putative proteins or pathways of carcinogenesis. Preliminary results from trials incorporating molecularly-targeted agents have shown a promising role for these compounds in the management of both locally advanced and recurrent/metastatic squamous cell carcinoma of the head and neck. The Symposium brought a clear message. The management of squamous cell carcinoma of the head and neck has evolved considerably, and with the advent of newer chemotherapeutic agents and molecularly targeted therapies, this field will continue to expand over time.
BMC Proceedings · 2013 · 0 citations · open access
Targeting uroporphyrinogen decarboxylase for head and neck cancer treatment
AbstractBackground Head and neck cancer (HNC) is the 8 most common malignancy worldwide. Despite advances in therapeutic options over the last few decades, treatment toxicities and overall clinical outcomes have remained disappointing, underscoring a need to develop novel therapeutic approaches, particularly those that enhance tumor cell death, while minimizing damage to the surrounding normal tissues.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
